Keymed Biosciences Inc. (incorporated in the Cayman Islands) filed its Monthly Return for the period ended 30 April 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised Capital • Authorised share count stayed at 500.00 million ordinary shares with a par value of USD 0.0001, representing total authorised capital of USD 50,000.

Issued Shares and Treasury Position • Issued shares (excluding treasury shares): 298.74 million. • Treasury shares: none. • No share issuances, cancellations, repurchases or treasury movements occurred in April 2026.

Public Float Compliance • The company affirmed compliance with the Main Board’s minimum public float requirement of 25% for its ordinary shares.

Capital Instruments • The return records no outstanding or new share options, warrants, convertible securities, or other agreements that could give rise to additional share issuance.

Management Sign-off • The filing was authorised by Executive Director Dr. Bo Chen on 6 May 2026.

The absence of share movements and continued adherence to listing rules indicate capital stability for the reporting month.